-+ 0.00%
-+ 0.00%
-+ 0.00%

Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate

Benzinga·03/31/2026 14:15:18
Listen to the news
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over losses of $(2.80) per share from the same period last year.